Citi analyst David Lebowitz reiterated a Buy rating and $58.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst comments "BridgeBio ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE